Hypera S.A. (BVMF: HYPE3)

Market Cap	11.63B
Revenue (ttm)	7.78B
Net Income (ttm)	1.57B
Shares Out	632.68M
EPS (ttm)	2.46
PE Ratio	7.46
Forward PE	7.69
Dividend	0.68 (3.72%)
Ex-Dividend Date	Dec 30, 2024

Volume	4,946,100
Average Volume	4,991,246
Open	18.09
Previous Close	18.09
Day's Range	17.78 - 18.40
52-Week Range	16.62 - 34.95
Beta	0.44
RSI	46.38
Earnings Date	Feb 21, 2025

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,301
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2023, Hypera's revenue was 7.91 billion, an increase of 4.88% compared to the previous year's 7.55 billion. Earnings were 1.65 billion, a decrease of -2.87%.